ELN 2017 Classification Significantly Impacts on the Risk of Early Death in Acute Myeloid Leukemia Patients Receiving Intensive Induction Chemotherapy

被引：0

作者：

Froim, Naama Keren ^{[1
]}

Heering, Gabriel ^{[2
]}

Sharvit, Gal ^{[2
]}

Zlotnick, Maya ^{[3
]}

Nagler, Arnon ^{[4
]}

Shimoni, Avichai ^{[5
]}

Avigdor, Abraham ^{[6
]}

Canaani, Jonathan ^{[7
]}

机构：

[1] Sheba Med Ctr, Tel Hashomer, Israel

[2] Chaim Sheba Med Ctr, Tel Hashomer, Israel

[3] Chaim Sheba Med Ctr, Div Hematol & Bone Marrow Transplantat, Ramat Gan, Israel

[4] Chaim Sheba Med Ctr, Div Hematol, Tel Hashomer, Israel

[5] Chaim Sheba Med Ctr, Div Hematol & Bone Marrow Transplantat, Ramat Gan, Israel

[6] Chaim Sheba Med Ctr, Div Hematol & Bone Marrow Transplantat, Tel Hashomer, Israel

[7] Sheba Med Ctr, Div Hematol, Giv'atayim, Israel

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-145551

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3392

引用

页数：3

共 50 条

[1] ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy
Keren-Froim, Naama
Heering, Gabriel
Sharvit, Gal
Zlotnik, Maya
Nagler, Arnon
Shimoni, Avichai
Avigdor, Abraham
Canaani, Jonathan
ANNALS OF HEMATOLOGY, 2022, 101 (02) : 309 - 316
[2] ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy
Naama Keren-Froim
Gabriel Heering
Gal Sharvit
Maya Zlotnik
Arnon Nagler
Avichai Shimoni
Abraham Avigdor
Jonathan Canaani
Annals of Hematology, 2022, 101 : 309 - 316
[3] Incidence and Risk Factors for Bleeding in Patients with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Versluis, Jurjen
Flamand, Yael
Haydu, Erika J.
Vedula, Rahul S.
Charles, Anne
Copson, Kevin
Wolach, Ofir
Bendapudi, Pavan
Belizaire, Roger
Neuberg, Donna S.
Luskin, Marlise R.
Lindsley, R. Coleman
BLOOD, 2020, 136
[4] Economic burden in US patients with newly diagnosed acute myeloid leukemia receiving intensive induction chemotherapy
Huggar, David
Knoth, Russell L.
Copher, Ronda
Cao, Zhun
Lipkin, Craig
McBride, Ali
LeBlanc, Thomas W.
FUTURE ONCOLOGY, 2022, 18 (32) : 3609 - 3621
[5] Patterns of Undertreatment Among Patients with Acute Myeloid Leukemia (AML) Not Receiving Standard Intensive Induction Chemotherapy
Hubscher, Elizabeth
Sikirica, Slaven
Bell, Timothy J.
Brown, Andrew
Welch, Verna L.
Russell-Smith, Alexander
D'Amico, Paul G.
BLOOD, 2020, 136
[6] Robust Parsing and Automated ELN Risk Classification for Acute Myeloid Leukemia
Silgard, Emily
Fang, Min
BLOOD, 2017, 130
[7] ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation
Hansen, Doris K.
Kim, Jongphil
Thompson, Zachary
Hussaini, Mohammad
Nishihori, Taiga
Ahmad, Anam
Elmariah, Hany
Faramand, Rawan
Mishra, Asmita
Davila, Marco L.
Khimani, Farhad
Lazaryan, Aleksandr
Sallman, David
Liu, Hien
Perez, Lia E.
Fernandez, Hugo
Nieder, Michael L.
Lancet, Jeffrey E.
Pidala, Joseph A.
Anasetti, Claudio
Bejanyan, Nelli
TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (03): : 256.e1 - 256.e7
[8] Evaluation of Early Discharge after Intensive Induction Chemotherapy in Adults with Acute Myeloid Leukemia
Al-Bahou, Amanda
Richter, Katherine A.
Snyder, Matthew
Rockwell, Sarah J.
Yun, Seongseok
Kubal, Timothy E.
BLOOD, 2021, 138
[9] INDUCTION CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
Lee, J. -H.
Joo, Y. -D.
Kim, H.
Bae, S. H.
Kim, M. K.
Zang, D. Y.
Lee, J. -L.
Lee, G. W.
Lee, J. -H.
Park, J. -H.
Kim, D. -Y.
Lee, W. -S.
Ryoo, H. M.
Hyun, M. S.
Kim, H. J.
Min, Y. J.
Lee, K. -H.
ANNALS OF ONCOLOGY, 2012, 23 : 24 - 24
[10] Therapy for acute myeloid leukemia: intensive timing of induction chemotherapy
Wells R.J.
Woods W.G.
Buckley J.D.
Arceci R.J.
Current Oncology Reports, 2000, 2 (6) : 524 - 528

← 1 2 3 4 5 →